Pro 2013-022 (Jianfeng Group Short Finance Payment Announcement)
Release time:
2020-08-05
Stock Abbreviation: Jianfeng Group Stock Code: 600 668 Announcement Number: Pro 20 13-022
Zhejiang Jianfeng Group Co., Ltd. 2012 First Phase
Short-term Financing Bonds 2013 Payment Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
In order to ensure the smooth payment of 12 peak CP001 (bond code: 041259041) and facilitate investors to receive the payment funds in time, the relevant matters are hereby announced as follows:
1. the basic information of the current bond
1. Issuer: Zhejiang Jianfeng Group Co., Ltd.
2. Bond name: zhejiang Jianfeng Group Co., Ltd. 2012 First Issue of Short-term Financing Bonds
3. Bond Abbreviations: 12 Peak CP001
4. Bond Code: 041259041
5. Total Issue: 0.2 billion yuan
6. Bond Interest Rate for Interest Period: 6.30
7. Maturity Date: on July 13, 2013
2. payment method
bonds held in trust in the inter-bank market clearing house co., ltd. shall be transferred to the bank account designated by the bondholder by the inter-bank market clearing house co., ltd. In the event of a legal holiday on the interest payment date or maturity date of the bond, the time for the transfer of funds will be extended accordingly. If the bondholder's capital transfer path changes, the new capital transfer path shall be notified to the Interbank Market Clearing House Co., Ltd. in a timely manner before payment. If the bondholder fails to notify the Interbank Market Clearing House Co., Ltd. of the change in the transfer path of the funds and cannot receive the funds in time, the issuer and the Interbank Market Clearing House Co., Ltd. shall not bear any losses arising therefrom.
3. the relevant institutions
1. Issuer: Zhejiang Jianfeng Group Co., Ltd.
Contact: Fu Zhijian
Tel: 0579-82326868
2. Lead Underwriter: CITIC Bank Co., Ltd.
Contact: Wang Wanjun
Tel: 010-655582 51
3. Custodian: Interbank Market Clearing House Co., Ltd.
Contact Department: Operations Department
Contact: Xie Chenyan, Chen Gongrong
Tel: 021-63325290, 63323832
This is hereby announced.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
July 8, 2013
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page